Exogenous surfactant therapy for ARDS

A Maruscak, JF Lewis - Expert Opinion on Investigational Drugs, 2006 - Taylor & Francis
A Maruscak, JF Lewis
Expert Opinion on Investigational Drugs, 2006Taylor & Francis
Regardless of the cause, a common pathophysiological feature of patients with acute
respiratory distress syndrome is a dysfunction of the endogenous surfactant system.
Although exogenous surfactant therapy has proven to be an effective treatment for neonatal
respiratory distress syndrome, no similar current effective therapy exists for patients with
acute respiratory distress syndrome. This is mainly due to the complexity of the lung injury
that is involved with this disorder. Results from clinical trials, to date, have failed to show an …
Regardless of the cause, a common pathophysiological feature of patients with acute respiratory distress syndrome is a dysfunction of the endogenous surfactant system. Although exogenous surfactant therapy has proven to be an effective treatment for neonatal respiratory distress syndrome, no similar current effective therapy exists for patients with acute respiratory distress syndrome. This is mainly due to the complexity of the lung injury that is involved with this disorder. Results from clinical trials, to date, have failed to show an improvement in patient survival after administration of exogenous surfactant; however, ongoing and future research efforts suggest that this therapy may eventually be feasible.
Taylor & Francis Online